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Abstract
Background: There is no clear consensus regarding optimal indications or timing of initial or repeat kidney biopsy
in the management of pediatric systemic lupus erythematosus (pSLE).
Methods: A web-based survey was designed to assess current practice patterns among pediatric nephrologists and
pediatric rheumatologists and distributed to members of Midwest Pediatric Nephrology Consortium (MWPNC) and
Childhood Arthritis and Rheumatology Research Alliance (CARRA).
Results: Respondents included 111 rheumatologists and 71 nephrologists from 65 and 34 centers, respectively.
Numbers of years in sub-specialty practice were comparable. Rheumatologists and nephrologists frequently collaborate
in the care of children with lupus nephritis (LN). More than 90 % of respondents refer patients to each either other after
diagnosing LN. Over 60 % describe shared decision making regarding when to perform kidney biopsy and how
to interpret biopsy findings. Many pediatric nephrologists consider biopsy to be of higher risk for complication in
pSLE and alter their standard pre-or post-biopsy management.
Conclusions: It is uncommon for pediatric nephrologists to manage LN without input from pediatric
rheumatologists and vice versa. Consensus exists between specialties in general, and practice differences that
exist occur between individual physicians rather than between specialties. A systematic approach to biopsy may
result in improved health related outcomes in pSLE.
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Background
Approximately 50 % of patients with pediatric-onset sys-
temic lupus erythematosus (pSLE) will develop some
form of lupus nephritis (LN) [1]. This results in in-
creased risk for renal failure, cardiovascular disease and
death. LN is a serious disease that requires prolonged
therapy with complex treatment plans and often toxic
therapy. The histopathology seen on kidney biopsy is
often central to the choice of therapy and disease
management. The American College of Rheumatology
(ACR) developed guidelines to assist physicians caring
for adult patients with SLE in deciding when to perform
a first kidney biopsy (Table 1) [2]. Several pediatric rheu-
matologists and nephrologists worry that applying these
guidelines to all children may be inappropriate, and the
editorial accompanying the publication of the ACR
guidelines warns that they should not be applied to chil-
dren or even adult males [3]. However, pediatric specific
guidelines are currently not available.
Although classification of LN according to renal histo-
pathology is essential in guiding appropriate therapy,
there remains disagreement over the classification
* Correspondence: wenderfe@bcm.edu
1Pediatric Nephrology, Texas Children’s Hospital, Baylor College of Medicine,
Houston, TX, USA
Full list of author information is available at the end of the article
© 2015 Wenderfer et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution
License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Wenderfer et al. Pediatric Rheumatology  (2015) 13:26 
DOI 10.1186/s12969-015-0024-x
system that best predicts prognosis or response to ther-
apy [4]. The World Health Organization (WHO) classifi-
cation is still used by some pathologists even after
publication of a newer classification by the International
Society of Nephrology in collaboration with the Renal
Pathology Society (ISN/RPS) in 2003 [5]. The activity
index (AI) and chronicity index (CI) as developed by
Morel-Marogel et al. and refined by Austin et al. [6] for
proliferative classes of LN are now used for all classes by
some pathologists. Three groups have published the utility
of histopathological classification, AI, and CI in their pSLE
cohorts in Canada [7, 8] and Thailand [9], but additional
evidence from other pediatric centers is needed.
The Joint European League Against Rheumatism
(EULAR) and the European Renal Association-European
Dialysis and Transplant Association (ERA-EDTA) rec-
ommend repeat kidney biopsy 6-months after induction
therapy for LN in children and adults [1], but this has
not been universally adopted. The topic has been
reviewed [4, 10, 11] and approaches for repeat biopsy
have been proposed [12–14], but consensus is lacking.
Practices include the assessment of decreases in AI or
changes in class after induction therapy, increases in AI
or CI in refractory disease, absence of disease activity
prior to weaning maintenance medication, or confirm-
ation of relapse in patients with kidney flares. Reports of
findings from repeat biopsies performed 6–to 9-months
after 3–, 6–, and 9–months of induction therapy for
proliferative LN in pSLE have been published [15–17],
but there have been no studies of repeat biopsy in chil-
dren with class V membranous LN.
There is considerable variation in pre-biopsy prepar-
ation and biopsy technique utilized in children undergo-
ing biopsy for LN [18, 19]. Pediatric nephrologists at
many centers perform their own biopsies, but other cen-
ters rely on interventional radiology to perform all or se-
lect “high risk” biopsies [19]. SLE patients are often taking
aspirin, non-steroidal anti-inflammatories, or anticoagula-
tion which most but not all physicians recommend stop-
ping before biopsy, but the variation in length of time
between stopping and performance of biopsy has not been
studied. The risk of complications after kidney biopsy in
children is between 0–14 % [11, 18, 20–22], and risks of
major complications such as prolonged gross hematuria
and large perinephric hematoma range from 3–7 %. Rou-
tine U/S performed 2 weeks after kidney biopsy identified
intra-renal or peri-renal hematomas in 40 % of children,
all of which resolved without further complication [23].
Reported predictors of complications include anemia
and azotemia, but concerns exist with platelet dysfunc-
tion, recent or current anti-coagulation, solitary kidney,
small kidneys, and advanced CKD [24]. Although pSLE
patients were included in these cohorts, the numbers
were too small to assess the effects of underlying sys-
temic vasculitis, anti-phospholipid antibodies, or hyper-
tension on complication rates. Some centers transfuse
for anemia and thrombocytopenia in order to biopsy
prior to starting induction therapy, whereas other cen-
ters treat presumptively and biopsy weeks or months
into treatment.
Routine post-biopsy care also varies tremendously among
pediatric nephrologists [18, 19, 23, 25]. Some observe all
patients overnight whereas others discharge low risk chil-
dren home after same day procedure [23]. For pSLE, prac-
tice variation may in part reflect the involvement of
different sub-specialists in the care of the patients, most im-
portantly pediatric nephrologists and rheumatologists.
In this study, we describe practice patterns related to
kidney biopsy of children with LN, compare the varia-
tions in practice among and between pediatric nephrolo-
gists and rheumatologists, and assess how these two
sub-specialties interact in clinical decision making. We
present and discuss the results of a survey addressing
specifically in pSLE the approach to first biopsy, ap-
proach to repeat biopsy, mechanisms for obtaining biop-
sies, and methods for interpretation of results.
Methods
Practice patterns were assessed with an online survey
sent to 300 members of the CARRA and 160 members
of the MWPNC via SurveyMonkey in January 2014. The
survey included 26 questions designed to delineate
current clinical practice in the approach to renal biopsy
in pSLE. Respondents had the option of disclosing their
institution. Respondents were uniquely identified by IP
address and date of response. Nineteen questions were
directed towards both pediatric rheumatologists and
pediatric nephrologists, two specifically directed towards
pediatric rheumatologists, and 5 specifically towards
pediatric nephrologists (See Additional files 1 and 2).
The survey questions addressed the following domains:
(1) Decision making for first biopsy (who decides on ne-
cessity of biopsy); (2) Collaboration (consultation of
rheumatologists by nephrologists and vice versa, use of
Table 1 American College of Rheumatology biopsy guidelines
(adapted from Table 2 in reference 2)
1) Increasing serum creatinine without compelling alternative
causea, or
2) Confirmed proteinuria of≥ 1 g per 24-hrsb, or
3) Combinations of the following, assuming the findings are
confirmed within a short period of time and in the absence
of alternative causes:
• Proteinuria≥ 0.5 g per 24-hrsb plus hematuriac, or
• Proteinuria≥ 0.5 g per 24-hrsbplus cellular casts.
aAlternative causes include sepsis, hypovolemia, or medication
bFor proteinuria, either timed urine collections or spot urine protein/creatinine
ratios are acceptable, but cutoffs for the latter are not specified
cHematuria is defined as ≥ 5 RBCs per high powered field
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multidisciplinary conferences to discuss biopsy results
and treatment); (3) Decision making for repeat biopsy
(for re-assessing histopathology changes in cases of re-
fractory disease, response to therapy, and/or relapse);
and (4) Biopsy procedures (who performs biopsy, avail-
ability of dedicated renal pathologist, pre-and post-
biopsy laboratory assessment, overnight-stay vs. same-
day discharge, classification systems, and use of activity
and chronicity indices). This survey and the data analysis
plan for this experimental research reported in the
manuscript was performed with the approval of the In-
stitutional Review Board at Northwestern University.
Hematuria is defined as ≥ 5 RBCs per high power field.
Protocol biopsy is defined as a routinely scheduled bi-
opsy performed on defined sets of pSLE patients for the
purpose of modifying immunosuppression therapy, ra-
ther than a biopsy performed in response to changes in
clinical or laboratory monitoring of patients.
Statistical approach: Groups were compared with
Fischer’s exact test for categorical variables, and stu-
dent t test for continuous variables. Significance was
set at p = 0.05.
Results
There were 182 respondents to the survey. Of these, 39 %
indicated that they were pediatric nephrologists and
51 % were pediatric rheumatologists. There were no
dual boarded pediatric nephrologist/rheumatologists
who responded to the survey. Response rates were approxi-
mately 44 % of all pediatric nephrologists and 37 % of all
pediatric rheumatologists. Of respondents who disclosed
their primary institution, at least 65 of the 92 pediatric
rheumatology centers involved in CARRA (71 %) and 34 of
the 51 pediatric nephrology centers (67 %) with member-
ship in the MWPNC were represented. Some institutions
were represented by more than one respondent in one or
both sub-specialty. Respondents were evenly distributed
across the range of years in practice, with about a quarter
each practicing 0–5, 6–10, 11–20, or >20years in their spe-
cialty (Table 2). There was no difference in years in practice
between pediatric nephrologists and rheumatologists.
Respondents were representative of pediatric centers
with a broad range of pSLE populations, based on the
number of cases presenting each year. Four percent of re-
spondents reported that their institution performs biopsies
on > 20 pediatric patients per year; 21.0 %, on 11–20
patients per year; 38.1 %, on 6–10 patients per year; and
36.9 %, on fewer than 5 patients per year.
Decision making for first biopsy
Results from our survey show that 78 % of respondents
intend to follow ACR adult guidelines for recommend-
ing kidney biopsy in their pSLE patients (Table 3),
equally divided by pediatric subspecialty. However, when
asked about specific scenarios, only 28.8 % actually
followed the guidelines. Hematuria alone warranted bi-
opsy according to 25.0 %; proteinuria alone (defined as
>150 mg/24h or a spot urine protein/creatinine ratio > 0.2
mg/mg), according to 58.2 %. Two pediatric rheumatolo-
gists and 2 pediatric nephrologists (each at separate insti-
tutions) routinely recommend or perform kidney biopsy
in any patient with a new diagnosis of pSLE, regardless of
the clinical findings.
Most respondents (66.5 %) have their patients’ biopsies
read by a dedicated renal pathologist at their primary insti-
tution, although 21.2 % use a local general pathologist. The
remaining 12.3 % have their biopsies sent out to a renal
pathologist at another institution. Pathologists utilize the
WHO grading system (33.2 %), the ISN/RPS grading
system (22.4 %), or both (33.0 %). A total of 9.5 % of
respondents were unsure of which grading system their
pathologists were using (11.6 % of nephrologists vs. 8.2 %
of rheumatologists). For diffuse proliferative GN, the activ-
ity and chronicity indices were provided routinely to 80.9 %
of respondents, whereas 2.3 % received only the activity
index, 1.1 % received only the chronicity index, and 15.2 %
worked with pathologists who did not provide either.
Collaboration
More than 90 % of pediatric rheumatologists and ne-
phrologists refer their patients with pSLE to the other
provider after a diagnosis of nephritis is made. There are
Table 2 Provider and center characteristics are comparable
between groups*
Pediatric Rheumatologists Pediatric Nephrologists
Respondents 111 71
‘How long have you been practicing your specialty?’
<5 years 26 (23 %) 18 (26 %)
6-10 years 27 (24 %) 19 (27 %)
11-20 years 29 (26 %) 15 (21 %)
>20 years 29 (26 %) 18 (26 %)
‘How many new pSLE patients per year are seen at your institution?’
<5 16 (15 %) 12 (18 %)
6-10 37 (34 %) 24 (36 %)
11-20 38 (35 %) 14 (21 %)
>20 19 (17 %) 16 (24 %)
'How many kidney biopsies on pSLE patients are performed each year
at your institution?’
<5 41 (38 %) 24 (35 %)
6-10 43 (40 %) 24 (35 %)
11-20 21 (19 %) 16 (24 %)
>20 3 (3 %) 4 (6 %)
*Numbers (and percentage) of each group of sub-specialist are subdivided by
the number of years practicing their specialty, recall on the number of new
patients seen at their center in a typical year, and recall on the typical number
of kidney biopsies performed (initial and repeat) per year
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very few pediatric nephrologists who do not have access
to a pediatric rheumatologist at their primary institution
(3.9 %, n = 3), and 2 of those 3 have an internal medicine
rheumatologist at their institution who care for children.
Similarly, only 3.6 % of pediatric rheumatologists (n = 4)
do not have access to a pediatric nephrologist at their
primary institution. The decision to perform a kidney
biopsy in a patient with pSLE is made by 62.5 % of re-
spondents only after discussions are held between
nephrology and rheumatology. Only 29.6 % of respon-
dents stated that the decision was made by the
pediatric nephrologists alone; and only 7.8 %, by the
pediatric rheumatologist alone.
Pediatric rheumatologists report viewing the tissue
slides together with their pediatric nephrologist and path-
ologist 49.1 % of the time and without a pathologist 2.7 %
of the time. Pediatric rheumatologists report reviewing tis-
sue section slides 14.6 % of the time with the pathologist
separately from nephrology, and 33.4 % of pediatric rheu-
matologists review only the biopsy report.
Decision making for repeat biopsy
There were no significant differences in the proportion
of pediatric rheumatologists or nephrologists that would
recommend/perform repeat renal biopsies under specific
instances (Table 4). For proliferative LN (class III or IV),
Table 3 Tendency to agree on when to deviate from ACR guidelines for first biopsy in pSLE
Pediatric Rheumatologists Pediatric Nephrologists
Respondents 108 69
“Do you follow ACR guidelines for deciding to obtain a first kidney biopsy in a SLE patient” *
Yes 83 (77 %) 56 (81 %)
No 25 (23 %) 13 (19 %)
Affirmative responses, sub-divided by years in practice
<5 17 (68 %) 15 (83 %)
6-10 21 (78 %) 14 (78 %)
11-20 26 (90 %) 14 (100 %)
>20 19 (70 %) 12 (67 %)
unspecified 1 (100 %)
“Do you deviate from the ACR guidelines in your decision to obtain a first kidney biopsy? If so under which circumstances?”
Affirmative responses for hematuria only 37 (34 %) 7 (10 %)
Affirmative responses for proteinuria only (>150mg/day and/or UPC > 0.2mg/mg) 64 (59 %) 40 (58 %)
*American College of Rheumatology (ACR) guidelines (see Table 1)were provided in the survey
Table 4 Variability between verses among pediatric rheumatologists and pediatric nephrologists in decision to perform repeat biopsy
Pediatric Rheumatologists Pediatric Nephrologists
Respondents* 109 68
“When do you repeat a kidney biopsy in a patient with proliferative SLE nephritis?
“After the initial induction period, regardless of response to treatment” 7 (6 %) 11 (16 %)
“After the initial induction period, only if there is no response to treatment” 44 (40 %) 31 (46 %)
“After the initial induction period, if there is only partial response to treatment” 26 (24 %) 19 (28 %)
“After remission and before withdrawal of all immunosuppression” 6 (6 %) 3 (4 %)
“After lupus flare with worsening in urine sediment, proteinuria, or kidney function” 75 (69 %) 47 (69 %)
“I do not routinely perform a repeat biopsy in lupus nephritis patients” 35 (32 %) 17 (25 %)
“When do you repeat a kidney biopsy in a patient with membranous SLE nephritis?
“After the initial induction period, regardless of response to treatment” 4 (4 %) 2 (3 %)
“After the initial induction period, only if there is no response to treatment” 33 (31 %) 24 (36 %)
“After the initial induction period, if there is only partial response to treatment” 14 (13 %) 12 (18 %)
“After remission and before withdrawal of all immunosuppression” 6 (6 %) 2 (3 %)
“After lupus flare with worsening in urine sediment, proteinuria, or kidney function” 71 (66 %) 48 (72 %)
“I do not routinely perform a repeat biopsy in lupus nephritis patients” 37 (35 %) 17 (25 %)
*Number and percentage of respondents indicating affirmatively that they would recommend repeat kidney biopsy in patients with pSLE, either for proliferative
or membranous LN
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there were 10 % (n = 18) who obtain true “protocol” biop-
sies in order to guide the dosing of induction therapy, and
5 % who re-biopsy patients in remission in order to guide
withdrawal of immunosuppression. However, 41.7 % would
obtain repeat kidney biopsy after induction therapy in pa-
tients with no response and 25 % would in patients with
only partial response. For patients in renal remission from
a proliferative nephritis who develop a renal flare, 69 %
would obtain another biopsy to guide therapy. Only 2.7 %
(n = 5) obtain repeat biopsy for non-renal lupus flares.
There were 29 % of respondents who stated that they do
not routinely repeat kidney biopsy after an initial patho-
logic diagnosis of proliferative LN. Of these 17 were
nephrologists and 35 were rheumatologists. Of the ne-
phrologists who do not re-biopsy, most stated that they
made biopsy decisions alone without consultation of their
rheumatology colleagues. Of the rheumatologists who do
not re-biopsy, only 2 stated that they made biopsy deci-
sions alone, and most did so in consultation with their
local pediatric nephrologists. The pediatric rheumatolo-
gists who do not recommend routine repeat biopsy tended
to have been practicing longer, whereas the pediatric ne-
phrologists who do not perform routine repeat kidney bi-
opsy tended to have been practicing for < 10 years. All 16
pediatric nephrologists practicing their specialty >20 years
stated that they will routinely re-biopsy patients with pro-
liferative LN for specific indications.
Repeat biopsy after initial diagnosis of membranous
LN (class V) differed very little from the practice follow-
ing initial diagnosis of proliferative LN (Table 3). Only
32.0 % would obtain repeat kidney biopsy after induction
therapy in patients with no response and 14.7 % would
in patients with only partial response. There were no sig-
nificant differences to the responses received from ne-
phrologists compared to rheumatologists.
Biopsy procedure
The majority (71.3 %) of respondents reported that at
their institutions, renal biopsies on pSLE patients with
nephritis were primarily performed by pediatric nephrolo-
gists. There were 19.9 % of respondents from institutions
where interventional radiology primarily performed the
biopsies, and respondents from the remaining 8.8 % of in-
stitutions had both pediatric nephrologists and radiolo-
gists performing proportionate numbers of biopsies.
Pediatric nephrologists were also questioned about their
preferences regarding the biopsy procedure itself. When
asked about pre-procedural laboratory testing, complete
blood count (CBC) is usually performed by 96 % of ne-
phrologists, partial thromboplastin time (PTT) by 94 %,
prothrombin time (PT) by 90 %, and INR by 76 %. Less
common laboratory testing included: type and screen
(36 %), platelet function testing (15 %), lupus anti-
coagulant (12.6 %), serum chemistries (2.8 %), urine
beta-HCG (2.8 %), urinalysis (1.4 %), and bleeding time
(1.4 %). Significant anemia (<7 g/dL) is thought to be a
contraindication to kidney biopsy by 35.4 % of nephrol-
ogists, whereas 5.4 % delay biopsy for Hgb < 8 g/dL and
1.4 % delay biopsy for Hgb < 9 g/dL until anemia can be
corrected. For significant thrombocytopenia (<50x10^3/
mcL) 58 % of nephrologists will defer biopsy. A few specif-
ically commented that they would transfuse PRBC, plate-
lets, or FFP in order to perform kidney biopsy without
delay. Other contraindications to renal biopsy included ac-
tive infection (58 %), uncontrolled hypertension (59 %),
and solitary kidney (17 %).
Non-steroidal anti-inflammatories (NSAIDs), including
aspirin, are routinely held by 85 % of pediatric nephrolo-
gists prior to biopsy. Most recommended holding these
drugs for 3–7 days prior to kidney biopsy (54.4 %), whereas
1.5 % held for 1 day, 11.8 % held for 2 days, 11.8 % held 8–
14 days, and 5.9 % held >14 days. NSAID use shortly be-
fore kidney biopsy is considered an absolute contra-
indication by 27 % of nephrologists. However, 14.7 % of
pediatric nephrologists would proceed with biopsy despite
NSAID use even for routine non-emergent kidney biopsies.
Some pediatric nephrologists consider recent NSAID use a
higher risk procedure warranting referral to interventional
radiology. Others start immunosuppressive therapy and
delay biopsy because of the NSAID use.
Of 68 pediatric nephrologists, 54.4 % routinely observe
patients overnight after kidney biopsy, whereas 38.2 %
routinely send patients without complications home on
the same day. Some nephrologists have particular con-
cerns about pSLE patients after biopsy, as suggested by
the fact that 7.4 % routinely observed their pSLE pa-
tients, but not patients with non-SLE kidney disease,
overnight before discharge (Fig. 1).
Discussion
Results of this survey of North American pediatric sub-
specialists clearly indicate that rheumatologists and ne-
phrologists do frequently work together in the care of
patients with pSLE and nephritis. Most pediatric ne-
phrologists and rheumatologists routinely review biopsy
results together as well. However there is a wide vari-
ation in approaches to performing and interpreting biop-
sies in pSLE among both sub-specialties.
Decision making for first biopsy
Pediatric rheumatologists and nephrologists appear to
value guidelines such as those published by the ACR,
based on the high proportion who stated that they use
them. However, the number of respondents who devi-
ated based on pediatric definitions of proteinuria sug-
gests that pediatric guidelines might be useful. The
numbers of respondents who deviated were comparable
between specialties. The differences in opinion on when
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to biopsy relate to number of years in practice in a more
complex manner. There were approximately equal pro-
portions of both pediatric nephrologists and pediatric
rheumatologists in each of the 4 groups (0–5 years, 6–10
years, 11–20 years, and > 20 years) (p-value = 0.114). The
only significant correlation between years in practice and
practice patterns was between the proportion of individ-
uals who had been practicing 11–20 years and adherence
to ACR guidelines (93 % compared to 70-76 % in the
other groups, p-value = 0.029).
Collaboration
The results of the survey show that it is uncommon for
pediatric nephrologists to manage LN without input
from pediatric rheumatologists. Of pediatric nephrolo-
gists responding, 90 % refer even their patients with
renal-limited pSLE to rheumatology before or after a
diagnosis of LN is made. If extra-renal manifestations
are also present, 97 % refer. Moreover, rheumatologists
are consulted by over 2/3rds of pediatric nephrologists
in making the decision to perform kidney biopsy, and
over half view the biopsy slides along with their pediatric
rheumatology colleagues.
There are also very few pediatric rheumatologists (<5 %)
who manage nephritis in pSLE without routinely seek-
ing the input of pediatric nephrologyOf these 6 rheu-
matologists, 3 make the decision to biopsy without
other consultation, but the other 3 seek guidance from
their nephrologist when deciding to order a kidney bi-
opsy, and 5 have their nephrologist perform the biopsy
once the decision is made. In addition, 5 of the 6
review renal biopsy results with their local pediatric
nephrologist.
Decision making for repeat biopsy
There is clearly no consensus regarding the indications
for repeat kidney biopsy in the management of prolifera-
tive or membranous LN. Just under one third of respon-
dents do not routinely recommend repeat biopsy in any
instance. Alternatively, 1.7 % routinely recommend re-
peat biopsies for any lupus flare, regardless of kidney in-
volvement. The most common practice is to repeat
kidney biopsy in patients who have an exacerbation of
their lupus which results in worsening of the urinary
sediment (2/3rds of respondents). The second most
common is to repeat biopsy at some time point during
induction therapy in non-responders (32 % for mem-
branous LN and 42 % for proliferative LN). Only a few
programs use “protocol” biopsies to guide duration of in-
duction or maintenance therapies in patients regardless of
response. Interestingly, there were no significant differ-
ences in the proportion of rheumatologists or nephrolo-
gists that engaged in the practice of recommending/
performing routine “protocol” repeat biopsy. This suggests
that in general pediatric rheumatologists and nephrolo-
gists are similar in their approach to repeat biopsy, and
that differences that exist are more common between in-
dividual physicians than between sub-specialties.
Biopsy procedures
Despite the ongoing role of pediatric nephrologists in
medical management of nephritis in pSLE, there might be
a shift in who is actually performing the biopsies. Many
nephrologists appear to consider pSLE to be a risk factor
for complications after kidney biopsy, and 12 (17 %) are
primarily referring their pSLE patients to interventional
radiology to perform the biopsy. It was not asked whether
these nephrologists perform kidney biopsies routinely on
their other patients. Of rheumatologists who completed
the survey, referral rates to nephrology and interventional
radiology are comparable. Therefore only 70 % of pediatric
nephrologists are choosing to perform biopsies of patients
with pSLE and only 70 % of pediatric rheumatologists are
having their local pediatric nephrologist performing the
biopsies.
Finally, there is great variability in the perceived safety
of kidney biopsies in pSLE. Most of this variability is
likely to reflect differences in perceived safety of kidney
biopsy in general. There are 38 % of pediatric nephrolo-
gists who discharge their pSLE patients the same day as
the procedure, similar to their practice with non-SLE pa-
tients. Conversely, 54 % observe both their pSLE and
non-SLE patients overnight. However, 8 % of pediatric
nephrologists do send most patients home on the day of
biopsy, but specifically observe pSLE patients overnight,
Fig. 1 A significant proportion of respondents manage pSLE
patients differently post-biopsy. Pediatric nephrologists were asked
when they typically discharged patients after kidney biopsy, in the
absence of complications. Most “keep all patients overnight for
observation, regardless of whether they have SLE,” as opposed to
discharging them home same day. However, 8 % “keep SLE patients
after kidney biopsy for overnight observation solely because of
possible increased risks associated with SLE.”
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due to perceived risk of complications. Identifying sources
of perceived increased risk of kidney biopsy in children
with lupus nephritis was beyond the scope of this study,
but hypotheses can be drawn from nephrologist responses
to survey questions on biopsy procedure. Possibilities in-
clude higher rates of anemia, thrombocytopenia, hyper-
tension, NSAID use, or anticoagulant use in pSLE patients
than in non-SLE patients, as well as a perceived need for
performing biopsy more urgently and less electively when
relative contraindications exist,
Limitations of our study include the possibility of se-
lection bias, recall bias, or reporting bias. Results of
survey-based studies can be inherently subject to signifi-
cant bias, and the strategies for survey distribution as
well as the response rates should always be taken into
account when interpreting survey data. Questions were
written by pediatric nephrologists and rheumatologists
together in order to minimize leading questions or error
due to differences in terminology. By surveying special-
ists participating in either CARRA or MWPNC, we may
have biased the results towards particular types of
pediatric centers. We chose to survey providers as op-
posed to centers, as differences in practice patterns
amongst providers in the same center are often encoun-
tered. There were no restrictions on how many pro-
viders could respond to the survey from any one center,
which could allow for bias. However, the large degree of
voluntary reporting of the respondents’ institution
allowed us to compare practice patterns within centers
with the highest degree of survey participation. The de-
gree of collaboration between sub-specialties may not be
applicable to primary care pediatric centers or centers
outside of the United States or Canada. However, the
strengths of the survey include the >40 % response rate,
the large number of institutions represented, and the
high proportion of completed surveys without missing
responses. Aside from reports of transplant kidney bi-
opsy, this study represents one of the only surveys to as-
sess approach to kidney biopsy for a particular kidney
disease, lupus nephritis, and the only survey to date that
compares the approaches between pediatric rheumatolo-
gists and nephrologists.
Conclusions
The results of this survey support the need for developing
a pSLE-specific approach to kidney biopsy. Agreement be-
tween pediatric nephrology and rheumatology should not
be an impediment. We support the formation of a collab-
orative group consisting of both pediatric nephrologists
and pediatric rheumatologists to find ways to improve the
diagnosis and treatment of LN and promote more collab-
orative research (PNR-CG, the Pediatric Nephrology and
Rheumatology Collaborative Group). Studies on the effect
of different strategies for performing repeat biopsy on the
outcomes of proliferative and membranous nephritis in
pSLE are warranted. Variability around practice remains
significant and it is becoming clear in medicine that
standardization can greatly improve outcomes.
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